It has been over five years since the start of the GlaxoSmithKline case that rocked the China healthcare industry. At the time, compliance, audit and legal teams were shocked by the prevalence of integrity and corruption issues that had apparently gone unidentified, despite the widespread practice of generating slush funds through fraudulent travel expense claims.… Continue Reading
For decades, U.S. prosecutors have touted their big victories over big pharma for violations of U.S. laws prohibiting bribery in the U.S. (the federal Anti-Kickback Statute) and abroad (the FCPA).
After paying tens of billions of dollars in fines and penalties, it appears that big pharma may have received the message and responded by taking compliance seriously and investing in the resources needed to identify and address risk areas.… Continue Reading
Last week, China’s chief healthcare regulator, the National Health and Family Planning Commission (NHFPC), published a significant revision to its earlier rules on donations to healthcare entities. This category of entities includes the nation’s network of state-run hospitals and clinics where about 90 percent of citizens get their healthcare.
The revised rule, titled Administrative Measures on Accepting Donations for Public Welfare by Healthcare Entities (for Trial Implementation) (the “New Donation Measures,” see original Chinese here and Covington’s English translation here), replaced the Administrative Measures on the Acceptance of Donations and Sponsorships (“2007 Measures”), which was promulgated in 2007.… Continue Reading
Michael Horn, president and CEO of Volkswagen Group of America, said Tuesday: “Our company was dishonest… we have totally screwed up.”
VW rigged U.S. car emission tests by installing software designed to cheat.… Continue Reading